Ragab Halla Mohamed, Samy Nervana, Afify Mie, El Maksoud Nabila Abd, Shaaban HebatAllah Mohamed
Department of Biochemistry, National Research Centre, Cairo, Egypt.
Department of Pathology, National Cancer Institute, Cairo University, Cairo, Egypt.
J Genet Eng Biotechnol. 2018 Dec;16(2):479-484. doi: 10.1016/j.jgeb.2018.03.002. Epub 2018 Mar 10.
Breast cancer is the most common cancer in females, it accounts for one third of all malignancies affecting women. Appropriate biomarkers play significant role in predicting the prognosis and decide the specific therapy to each patient. In this study we aimed at evaluating the value of Ki-67 as a prognostic marker in breast cancer patients and to analyze the associations between Ki-67 and their clinicopathological parameters. This study included 92 patients with developed non metastatic breast cancer and 10 women had benign breast tumor served as controls. We measured the serum level by ELISA technique and tissue expression of Ki-67 by immunohistochemical technique. Our results showed that there were no statistically significant differences in serum Ki-67 levels between the two studied groups. As for Ki-67expression in breast cancer cells, the score increases with increase of tumor size, grade, premenopausal, Ki-67 expression in estrogen and progesterone receptor positive tumors showed lower values than estrogen and progesterone negative tumors, while higher Ki-67 expression was more frequently associated with HER2-positive. In conclusion; our study supports the finding that tissue Ki-67 expression may add prognostic information to that obtained from classical prognostic factors and can provide data of significant value to other important prognostic indicators such as pathological grading, and axillary lymph node involvement.
乳腺癌是女性最常见的癌症，占所有影响女性的恶性肿瘤的三分之一。合适的生物标志物在预测预后以及为每位患者确定具体治疗方案方面发挥着重要作用。在本研究中，我们旨在评估Ki-67作为乳腺癌患者预后标志物的价值，并分析Ki-67与其临床病理参数之间的关联。本研究纳入了92例已发生非转移性乳腺癌的患者，另有10例患有乳腺良性肿瘤的女性作为对照。我们采用ELISA技术检测血清水平，采用免疫组化技术检测Ki-67的组织表达。我们的结果显示，两个研究组之间血清Ki-67水平无统计学显著差异。至于乳腺癌细胞中的Ki-67表达，其评分随肿瘤大小、分级、绝经前状态的增加而升高，雌激素和孕激素受体阳性肿瘤中的Ki-67表达值低于雌激素和孕激素阴性肿瘤，而较高的Ki-67表达更常与HER2阳性相关。总之，我们的研究支持以下发现：组织Ki-67表达可能会为从经典预后因素中获得的信息增添预后信息，并可为其他重要的预后指标（如病理分级和腋窝淋巴结受累情况）提供有重要价值的数据。
